{"analyses":[{"groupDescription":"t-test stratified for lineage and ploidy","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":".0062","pValueComment":"p-value from t-test after stratified for lineage and ploidy","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2015","value":"1688"},{"groupId":"OG001","spread":"2950","value":"2521"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"description":"Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m\\^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells.","dispersionType":"Standard Deviation","groups":[{"description":"4 hour High-Dose Methotrexate Infusion in upfront window treatment","id":"OG000","title":"4 hr"},{"description":"24 hour High-Dose Methotrexate Infusion in upfront window treatment","id":"OG001","title":"24 hr"}],"paramType":"MEAN","populationDescription":"The 286 patients randomized to treatment with high-dose methotrexate (HDMTX) who had methotrexate polyglutamate (MTXPG) concentration measured in bone marrow ALL cells .","reportingStatus":"POSTED","timeFrame":"42 hours after start of high dose methotrexate infusion (HDMTX)","title":"Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).","type":"SECONDARY","unitOfMeasure":"pmol/1,000,000,000 cells"}